Neurocrine Biosciences Inc. logo

NBIX

Neurocrine Biosciences Inc.

$136.03

Earnings Summary

Revenue
$515.2Mn
Net Profits
$147.7Mn
Net Profit Margins
28.67%
PE Ratio
54.89

Highlights

Revenue:

Neurocrine Biosciences Inc.’s revenue jumped 25.05% since last year same period to $515.2Mn in the Q4 2023. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 3.29% jump in its revenue since last 3-months.

Net Profits:

Neurocrine Biosciences Inc.’s net profit jumped 65.96% since last year same period to $147.7Mn in the Q4 2023. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 77.74% jump in its net profits since last 3-months.

Net Profit Margins:

Neurocrine Biosciences Inc.’s net profit margin jumped 32.71% since last year same period to 28.67% in the Q4 2023. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 72.08% jump in its net profit margins since last 3-months.

PE Ratio:

Neurocrine Biosciences Inc.’s price-to-earnings ratio after this Q4 2023 earnings stands at 54.89.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Neurocrine Biosciences Inc. post its latest quarter earnings

EPS Estimate Current Quarter
1
EPS Estimate Current Year
1

Highlights

EPS Estimate Current Quarter:

Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 1 - a -13.04% fall from last quarter’s estimates.

EPS Estimate Current Year:

Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current year stand at 1.

Key Ratios

Key ratios of the Neurocrine Biosciences Inc. post its Q4 2023 earnings

Earning Per Share (EPS)
1.44
Return on Assets (ROA)
0.09
Return on Equity (ROE)
0.13

Highlights

Earning Per Share (EPS):

Neurocrine Biosciences Inc.’s earning per share (EPS) jumped 63.64% since last year same period to 1.44 in the Q4 2023. This indicates that the Neurocrine Biosciences Inc. has generated 63.64% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Neurocrine Biosciences Inc.’s return on assets (ROA) stands at 0.09.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Neurocrine Biosciences Inc.’s return on equity (ROE) stands at 0.13.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2023-08-01
0.78
0.95
21.79%
2023-10-31
0.97
0.82
-15.46%
2023-05-03
0.13
-0.79
-707.69%
2024-02-09
1.15
1.44
25.22%